Press Releases

RSS feed

A new step forward to gene-medicine for AFM-Telethon : to produce and cure

AFM-Telethon has decided to take up a new challenge: to produce gene-medicines from innovative biotherapies developed in the laboratories part of its Biotherapies Institute for Rare Diseases at an industrial scale, and to give patients suffering from rare genetic diseases access to them at a fair and contained price. With this in view, the association … [Read more]

Telethon 2015: 4 families, 4 stories, 4 fights against rare disease

Four families, all affected by rare diseases, will be the ambassadors of thousands, all gathered around the message: “The Fight of Parents, The Life of Children.” On December 4th and 5th, together with Marc Lavoine, the official ambassador of Telethon 2015, four families will represent the fight of the AFM-Telethon.  Séthi, Léo, Nicolas and Marie … [Read more]

New gene therapy success in a rare disease

French teams from CIC Biothérapie (AP-HP/Inserm), from pediatric hematology department of Necker Hospital for Children (AP-HP), led by Marina Cavazzana, Salima Hacein Bey Albina and Alain Fischer and from Genethon led by Anne Galy (Genethon/Inserm UMR-S951), and English teams from UCL Institute of Child Health and Great Ormond Street Hospital in London led by Adrian … [Read more]

Genethon Postdoctoral Program Spring 2014

Genethon is launching an International Postdoctoral Program to attract excellent scientists who wish to pursue their career in the field of gene therapy.Postdoctoral research positions are available for a period of three years … Download the Postdoctoral Program Spring 2014

Généthon, the French AFM-Telethon laboratory, becomes the first not-for-profit to obtain authorization from ANSM to be a pharmaceutical manufacturer

Généthon, the AFM-Telethon laboratory, has received the authorization delivered by the National Agency for Drug Safety (ANSM) to become a pharmaceutical manufacturer. Its production center, Généthon BioProd, is now authorized to produce drugs for innovative treatments. This is a first for a laboratory created by an association of patients and financed thanks to the generosity … [Read more]

Myotubular Trust is supporting Généthon in developing gene therapy for Myotubular myopathy

The European charity Myotubular Trust announces its support to the development of a pre-clinical gene therapy trial for myotubular myopathy, a project co-ordinated by Dr. Anna Buj-Bello at Généthon (Evry, France). Read the press release

AFM-Téléthon and the National Seed Fund have joined forces

CDC Entreprises, a subsidiary of Caisse des Dépôts and a future bpifrance1 entity, has been mandated by the French government to manage the FNA as part of the Investing in the Future Programme (Programme d’Investissements d’Avenir). It is collaborating with AFM-Téléthon (French muscular dystrophy association organising French Téléthon), an association of patients and parents of patients, to help introduce … [Read more]

Chronic granulomatous disease : Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial

On January 10th, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London. Genethon is also seeking approval for this multicenter trial in Germany, Switzerland and France. In total the trial will include 20 patients … [Read more]

Rare diseases : 38 million Euro funding for research

European Union has announced 38 million Euro funding for research towards new treatments and for the development of a central global rare disease hub involving 70 institutions – including AFM-Telethon – that will allow scientists to share data from their genomics research projects. This will lead to faster diagnosis and better treatments and improve the … [Read more]

Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!